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Summary: The determination of 2'-5'-oligoadenylate synthetase in peripheral blood mononuclear cells is used
äs a biological response parameter during therapy with interferon and in the diagnosis of diseases related to
the interferon System. In this communication, some general aspects concerning the preparation of 2'-5'-
oligoadenylate synthetase from peripheral blood mononuclear cells and the incubation conditions of the 2'-
5'-oligoadenylate synthetase reaction are reported. Four analytical procedures for the determination of the
products formed during the 2'-5'-oligoadenylate synthetase reaction were comparatively investigated and the
advantages and limitations of the assays are discussed. As an example of possible clinical application, the
levels of 2'-5'-oligoadenylate synthetase were determined in the mononuclear cell fraction of peripheral blood
from healthy persons äs well äs from children with chronic myelogenous leukaemia.
Introduction
Interferons are (glyco)proteins with pleiotropic effects
(antiviral, antipröliferative, immunomodulative). The
molecular mechanisms of their action is not yet fully
understood, but some of the antiviral and perhaps
antiproliferative effects are probably related to the
so-called 2'-5'-oligoadenylate System (l, 2); treatment
of cells with interferon leads to the de novo synthesis
of 2'-5'-Qligpadenylate synthetase (fig. 1). This enzyme
is able to produce oligoadenylates from ATP in the
presence of double-stranded RNA(dsRNA) according
to the equation:
ATP => ppp5'A2' (p5'A)n^ + (n-l)PP,
(n = 2-14)
The'adenosine residues of these oligoadenylates are
liüked by phosphodiester bonds in the unusual 2'-5'-
position. 2'-5'-Oligoadenylates greater than the di-
meric form (n = 2) activate an endoribonuclease
(RNaseL) which cleaves mRNA. A third enzyme, 2'-
5'-oligoadenylate phosphodiesterase, destroys 2'-5'-
oligoadenylates, so that the RNase returns to its in-
active state. Additionally to ^-S'-oligoadenylates, 2'-
S'-Qligpadenylate-cores (^-S'-oligoadenylates without
the triphosphate residues on the terminal S'-position)
are also found in cells. They do not activate the
endoribonuclease, but they are also biologically active
(3).
The cellular levels of the 2'-5/-oligoadenylate synthe-
tase are subject to change under certain conditions,
e. g. during differentiation (4). It shows an especially
marked elevation after interferon treatment. There-
fore, the determination of 2'-5'-oligoadenylate synthe-
tase has been widely used in the diagnosis of different
diseases connected with the interferon System (5 — 12)
and äs a response parameter during interferon therapy
(13,14). Several methods for the determination of 2'-
5'-oligpadenylate synthetase in different cell types
have been described (for review see 1. c. (1)). All these
assays consist of three Steps: preparation of 2'-5'-
oligoadenylate synthetase from cells, incubation of
the enzyme with ATP and analysis of the reaction
products. However, because several different analyt-
ical procedures are used and incubation conditions
are not uniform, greatly differing results have been
reported (factor 10). The aim of our study was to
standardize the preparation and incubation condi-
tions for the determination of ^-S'-oligoadenylate
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synthetase / rTr~T—| ·%
ATP +· ppp5'A2'p5'A, ppp5'A2'p5'A2'p5'A, ppp5/A2'p5/A2'p5/A2/p5'A1... + PP
dsRNA dimer(n = 2) trimer(n = 3) tetramer (n = 4) ...(n « ,14)
RNase Lj *- RNase La
Degradation of mRNA (preferentially with partial dsRNA structures)
l
Inhibition of protein synthesis
Fig. l. The 2'-5'-oligoadenylate System.
synthetase in peripheral blood mononuclear cells, and
to compare the test System according to Schattner
(which is wideiy used in many laboratories) with some
other assays in order to find out which of them is
most suitable for application in the clinical laboratory.
2'-5'-Oligoadenylate synthetase levels were estimated
in peripheral blood mononuclear cells from healthy
persons. As an example of a clinical application, they




Enzymes (from Sigma, München)1:
1) Bacterial alkaline phosphatase, E. coli, type III, EC 3.1.3.1.
2) Snake venom phosphodiesterase, EC 3.1.4.1.
3) Creatine phosphokinase, bovine heart, type III, EC 2.7.3.2.
4) Hexokinase, bakers veast, type IV, EC 2.7.1.1.
Interferon- , Polyferon, 3.3 6 U/mg protein, Bioferon,
Laupheim
Agarose-Polyriboinosinic acid-Polyribocytidylic acid (AG-
POLY(I)-POLY(C)), type 6, Pharmacia, Freiburg,
(Poly(rI):(rC))-agarose beads
Rabbit reticulocyte lysate N 90, Amersham, Braunschweig
2'-5'-Adenosine-tetramer 5'-triphosphate, Amersham, Braun-
schweig
0 1. Bacterial alkaline phosphatase, E. coli, type III, Ortho-
phosphoric-monoester phosphohydrolase (EC 3.1.3.1)
2. Creatine phosphokinase, bovine heart, type III, ATP:
creatine N-phosphotransferase (EC 2.7.3.2)
3. Hexokinase, bakers yeast, type IV, ATP:Z>-hexose-6-phos-
photransferase (EC 2.7.1.1)
4. Snake venom phosphodiesterase, 5'-Exonuclease; Oligo-
nucleate 5'nucleotido-hydrolase (EC 3.1.4.1)
Radioactive-labelled compoünds (Amersham, Braunschweig):
1) Adenosine[5'-a-32P]-triphosphate, p2P]ATP, 0.37-1.85 TBq/
mmol
2) [2,8- 3H] Adenosine 5'-triphosphate, [3H]ATP, 1.1-1.85 TBq/
mmol




1) Lysis buffer: 20 mmol/1 HEPES, 5 mmol/1 magnesium ace-
täte, 120 mmol/1 potassium Chloride, 7 mmol/1 sodium hy^
drosulphite, glycerol, volume fraction 0.1, Nonidet P-40,
volume fraction 0.005, pH 7.5.
2) Buffer A: 10 mmol/1 HEPES, 50 mmol/1 potassium chloride,
7 mmol/1 sodium hydrosulphite, 20 mmol/1 magnesium ace-
tate, glycerol, volume fraction 0.2, pH 7.6.
3) Buffer B: Buffer A + creatine phosphokinase (3 g/l), crea-
tine phosphate (10 mmol/1), adenosine triphosphate
(5 mmol/1), pH 7.6 (frozen in aliquots at —70 °C).
4) Incubation buffer 1: Buffer B + 1.85 GBq/1 [32P]ATP
(Schatiner-zssay).
5) Incubation buffer 2: Buffer B + 1.85 GBq/1 pH]ATP (Lo-
demann/Ball & White assay).
6) Radiobinding assay buffer 1: 85 mmol/1 potassium chloride,
20 mmol/1 Tris · HC1, 5 mmol/1 magnesium äcetate, l mmol/1
adenosine triphosphate, glycerol, volume fraction 0.05, pH
7.6.
7) Radiobinding assay buffer 2: Buffer l minus adenosine tri-
phosphate.
Methods
In figure 2, a schematic survey of the test Systems described
subsequently is given.
Preparation of cell lysates
Peripheral blood mononuclear cells were isolated üsing lym-
phoprep (Nyegaard, Oslo). The isolated cells were suspended
in MEM (minimal essential medium coiitaining 5% foetal calf
serum). The ceil Suspension (l 106 cells per ml) was incubated
at*37°C ovefnight without or with 1QOO U/ml interferon-a.
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I. Isolation of 2'-5'-oligoadenylate synthetase
Pcripherul blood mononuclcar cellsι
Cell lysis
Binding of 2'-3'-oligoadenylate synthetase on poly (r!);(rC)-agarose beads
II. 2'-5'-Oligoudenylatc synthetase reaction
pppA »» pppApA + pppApApA + pppApApApA + ... + PP (Schaltner assay: («JATP)
(Lodcmann &. Ball assay: (3H]ATP)
(ATP) dimer trimer te t ramer (PPP(ApA)n) (Radiobinding assay:ATP)
Schatlner assay
ppp*A + ppp*(Ap*A)„ + PP
III. Analysis of reaction products
Lademann assay Ball & Whiie assay Radiobinding assay
lBacterial | alkalinephosphatase
pppA* + ρρρ(Α·ρΑ*)η + PP
l
pppA* + ppp(A*pA*)„ + PP competition of ppp(ApA)„ and (2-
on the binding sitcs of
Bacterial | alkatine
phosphatase
P + P» + A + (Ap*A)0
ι
Alumina column
P + A* + (A*pA*)„
J
l
Separation of (Ap*A)n from P*
DEAE-cellulose column
Separation of(A*pA*)ft from A*
Bacterial l alkaline
| phosphatase
P + A* + (A*pA*)„
- l
Transfer on DEAE-cellulose filters
RNaseL
ι
Washing out of A*
Transfer on NC-filters
Washing out of unbound
(2-5A)i«P]pCp
Cerenkov-counung of (Ap*A)n Liquid scintillation counting of
(A'pA*),,
Liquid scintillation counting of Liquid scintillation counting of
(A*pA*)„ (2-5A)[MPJpCp bound on RNaseL
Fig. 2. Comparative survey of the 4 test Systems investigated for the determination of 2'-5'-oligoadenylate synthetase.
After centrifugation, the supernatant was removed completely
and the cell pellets were treated with lysis buffer (100 μΐ per
2 χ 106 cells, 10 minutes at 4 °C). After centrifugation (l 5 000 g,
8 minutes), the 2'-5'-oligoadenylate synthetase-containing su-
pernatant was collected and frozen at —70 °C.
Binding of 2'-5'-oligoadenylate synthetase on
poly(rI):(rC)^ag rose beads and perfprmance of the
2'-5'-oligoadenylate synthetase reaction
Poly(rI):(rC)ragarPse beads were washed with 20 mmol/1 so-
dium phosphate buffer containing 200,mmol/l sodmm Chloride,
pH 7.5 (this step, however, can be avoided). The beads were
suspended in buffer A (l + l by vol.) and 40 ul aUquots were
transferred into Eppendorf cups. After brief centrifugation and
removal of the superaatant, 20 ul cell extracts were added (25
minutes incubation at room temperatufe). Following this bind^
ing reaction, the agarose-beads were washed twice with 750 ul
buffer A. The '̂-S'-p goadenylate synthetase reaction was
.started by addition of incubation buffer (20 μΐ), and the incu-
bation was carried put for 2^20 hours at 30 °C. The reaction
was stopped by heating the samples (2 minutes at 95 °C).
Until this step, the test procedure is the same for all fpur
methods described.
Analysis of the 2 /-5'-oligoadenylates formed during
the 2'-5 /-oligoadenylate synthetase reaction
All assays were carried out according to the original test pro-
tocols, with small modifications.
Schattner assay (16) (Standard and reference test System)
After the 2'-5'-oligoadenylate synthetase reaction, 20 μΐ bacte-
rial alkaline phosphatase (100 U/ml Trizma (140 mmol/1; Sigma,
M nchen) were added to the reaction vessels (l hour incubation
time at 37 °C). This step is carried out in the same way s in
the assays of Lodemann & Ball (see below and fig. 2).
After incubation with bacterial alkaline phosphatase, the P2P]-
labelled 2'-5'-oligoadenylate cores were separated from P2P] on
small columns, which were prepared in l ml Eppendorf Stand-
ard tips using 600 ul alumina Suspension (alumina, type WA-
4: acid; Sigma, M nchen, suspended in water, l -f l by vol.).
The columns were washed with 3 ml glycine-HCl (l mol/1,
pH 2). Samples (20 μΐ) were applied to the columns, and the
2'-5'-oligoadenylate cores were eluted with 3ml giycine-HCl
and their radioactivity determined
Principles ofevaluation of the Schattner assay
Because of the short half-life time of 32P (14.31 days), the
Performance of one set of experiments was carried out within
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2—4 weeks (usually 5 χ 50 determinations in duplicate using
5 χ 1.85 MBq [32P]ATP). For each set of experiments, the 2'-
5'-oligoadenylate synthetase activities in peripheral blood
mononuclear cells of 5 healthy persons (male and female, 20—
45 years of age) were delcrmined (normal collective). The cells
were left untreated, or they were pretreated with 1000 IU
interferon. The 2'-5'-oligoadenylate synthetase was determined
s described above. Each test protocol consisted of:
a) 100%-sample: 20 μΐ radioactive cocktail (20 μΐ incubation
buffer + 20 μΐ Trizma), suspended in 3 ml glycine-HCl.
b) test samples: radiolabeled 2'-5'-oligoadenylate cores, eluted
with 3 ml glycine-HCl ( s described above)
c) blank sample: samples processed exactly s test samples, but
using 20 μΐ lysis buffer instead of 20 μΐ cell lysate.
The incorporation of [32P] from [32P]ATP into 2'-5'-oligoaden-
ylate cores was estimated, e. g. after 20 hours incubation time.
The results are expressed s:
% radioactivity incorporated from [32P]ATP into 2'-5'-oligoad-
enylate cores per hour from a lysate of l O6 cells.
The mean value from 5 healthy donors (normal collective) was
arbitrarily set at 1.0. 2'-5'-oligoadenylate synthetase activity
present in the cell lysate from one of these 5 donors was adjusted
to this mean value by sample dilution. Aliquots of this sample
were frozen at — 70 °C and were subsequently used s an
internal reference sample for all further investigations using the
same Charge of [32P]ATP.• \
Additionally, the 2'-5'-oligoadenyIate synthetase activity was
estimated in peripheral blood mononuclear cells after in vitro
treatment with interferon (l 8 hours).
The ratio:
activity after interferon treatment
activity without interferon treatment
is expressed s the elevation factor.
Lodemann assay (14)
After treatment with bacterial alkaline phosphatase (see above),
samples were diluted with l ml Tris-HCl (0.5 mmol/1), pH 7.6.
Following centrifugation, l ml of the supernatant was applied
to DEAE-52 cellulose columns (Whatman DE 52), prepared in
l ml plastic syringes (packing volume: 600 μΐ). The columns
were equilibrated with Tris-HCl, pH 7.6.
After addition of 15 ml 0.5 mmol/1 Tris-HCl, pH 7.6 (elution
of pHJadenosine), the 2/-5/-oh'goadenylate cores were eluted
with 3 ml buffer (0.5 mmol/1 Tris-HCl, 0.2 mol/1 NaCl, pH 7.6).
l ml aliquots were mixed with 10 ml scintillation cocktail (Uni-
solve 100, Zinsser, Frankfurt), and counted.
Ball& White assay (17)
After treatment with bacterial alkaline phosphatase, 10 μΐ sam-
ples were spotted onto l cm2 DEAE-cellulose paper (Whatman,
DE 81), washed 8 times with distilled water and transferred
into scintillation vials. [3H]-labeled 2'-5'-oligoadenylate cores,
bound on the filters, were eluted with 300 mmol/1 KC1. The
radioactivity was measured after addition of 10 ml Unisolve.
Radiobinding assay (15)
For test performance, the following were added to Eppendorf
tubes:
a) 20 μΐ rabbit reticulocyte lysate (contains RNaseL)
b) 10 μΐ 2-5A [32P]pCp prediluted in buffer l, to achieve a
radioactive concentration of about 2 χ l O4 counts/min
10 μΐ
c) 1—20 μΐ sample (supernatant of the 2'-5'-oligoadenylate
synthetase reaction, diluted in distilled water). For establish-
ment of the calibration curve, l — 20 μΐ 2'-5'-adenylate tetra-
mer (1 — 5 nmol) were added instead of samples
d) Distilled water to a final test volume of 50 μΐ.
The tubes were incubated at 4 °C for 90 minutes. Subsequenlty,
the incubation mixture was transferred to nitrocellulose filters,
removed by suction, and the filters washed three times with
1ml of buffer 2. Radioactivity on the filter discs (2—5A
[32P]pCp bound on RNaseL) was counted after addition of 10
ml Unisolve 100.
Results
Isolation of 2'-5'^oligoadenylate synthetase
from lysates of peripheral blood mononu-
clear cells using poly(r!):(rC)-agarose bead$
Experiments were performed to determine the amount
of poly(r!):(rC)-agarose Suspension required to bind
the 2'-5'-oligoadenylate synthetase present in cell lys-
ates. As depicted in figure 35 30 μΐ were s fficient to
bind the enzyme in cell lysates from 4 χ l O5 peripheral
blood mononuclear cells pretreated with 1000 IU in-
terferon-α per ml.
Furthermore, we investigated whether enzymes that
attack either ATP or 2'-5'-oligoadenylates can influ-
ence the 2'-5'-oligo denylate synthetase reaction if
they are isolated s impurities on the poly(rI):(rC)-
agarose. As a model System for ATP-cons ming en-
zymes, hexokinase (in the presence of l mmol/1 glu-
cose) was added to the 2'-5'-oligoadenylate syiithetase
reaction mixture. Table l a shows that ADP formed
by the hexokinase reaction was reconverted coiii-
pletely to ATP in the presence of creatine phosphate
and creatine kinase. These reagents are therefore











Poly (rI):(rC)-agarose fae ds Ιμ(]
Fig. 3. Binding of 2'-5'-oligoadenylate synthetase (lysate from
4 χ l O5 peripheral blood mononucleair cells, pretreated
with 1000 IU interferon-α) on different amounts of poly
(r!):(rC)-agarose beads (Schattner assay).
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Tab. l a. Degradation of ATP (5 mmol/1) by hexokinase and
gl cose (l mmol/1)
a) in the absence
b) in the presence of an ATP regenerating System (10
mmol/1 creatine phosphate +100 kU/1 creatine
kinase)
(30 minutes incubation time at 37 °C)







Tab. l b. Degradation of 2'-5'-oligoadenylate cores during l
hour incubation with peripheral blood mononuclear
cell lysates (pretreated without or with 1000 U inter-
feron-α per ml) and with snake venom phosphodies-
terase s positive control.
Snake venom phosphodiesterase: 0.02 U per test







Cell lysate with interferon-a 0—4%
Cell lysate without interferon-a 0—4%
Snake venom phosphodiesterase 100%
In order to clarify whether any bound 2'-5'-oligoad-
enylate phosphodiesterase activity could influence the
2'-5'-oligoadenylate synthetase reaction, lysates of pe-
ripheral mononuclear blood cells and snake venom
phosphodiesterase, known to be able to split 2'-5'-
oligoadenylates (18), were added to the incubation
mixture after stopping the 2'-5'-oligoadenylate syn-
thetase reaction. Tabje Ib shows that degradation
occurs only in the presence of snake venom phospho^·
diesterase (positive control), but not in the presence
of cell lysate.
Time and concentration dependence of the
2'-5'-oligoadenylate synthetase reaction
Under Standard incubation conditions, the 2'-5'-oli-
goadenylate synthetase reaction follows a linear
course for at least 20 hours, if the enzyme is bound
to poly(rI):(rC)-agarose beads (fig. 4 a).
Figure 4b shows that there is also a linear correlation
between the turnover rate and the amount of cell
lysate (i. e. the amount of 2'-5'-oligoadenylate synthe-
tase).
5 10 15 20
Cell lysate [μϋ
3 6 1 4 2 0
Incubation time (h)
Fig. 4 a. Time dependence of the incorporation of radioactivity
from [32P]ATP into 2'-5'-oligoadenylate cores (20 μΐ
lysate from peripheral blood mononuclear cells,
2 χ l O6 cells per 100 μΐ), (Schaffner assay).
D —D Cells pretreated with interferon overnight
D—D cells incubated in cell culture medium overnight
Fig. 4 b. 2'-5'-Oligoadenylate synthetase activity (expressed s
radioactivity incorporated from [32P]ATP into 2'-5'-
oligoadenylate cores using different amounts of cell
lysates from peripheral blood mononuclear cells
(2 χ 106 cells per 100 μΐ), (Schattner assay).
D — D cells pretreated with interferon overnight
D^D cells incubated in cell culture medium overnight
Evaluation of the Schattner assay
In table 2, the turnover rate of the 2'-5'-oligoadenylate
synthetase reaction using the cell lysates of 5 healthy
donors is given. All experiments were carried out in
Tab. 2. 2'-5'-Oligpadenylate synthetase levels in peripheral blood mononuclear cells from healthy donors without and after
treatment with interferon-a (1000 i /ml)
Donor Radioactivity
counts/mm per




































45 644 ± 1783














100%-vaIue: 219014 ± 1857
Blank value: 668 ±14 '
Mean value of samples: 1.18 ± 0.2% radioactivity incorporated into 2'-5'-oligoadenylate cores per hour per l χ 10 cells
(arbitrarily set: 1.0)
Elevation factor: 2.3 ± 0.26
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duplicate (CV was usually between 5 and 10%). The
mean basal level of the 2'-5'-oligoadenylate synthetase
activity in this set of experiments was 1.18 + 0.2%
radioactivity incorporated into 2'-5'-oligoadenylate
cores per hour per 106 cells (CV: 16.8%). This value
was arbitrarily set äs l .0 and was used äs the reference
for all other determinations during a ränge of exper-
iments carried out with the same Charge of [a-32P]ATP.
The elevation factor was 2.3 ± 0.26 (CV: 11.3%).
In two other series of experiments carried out in the
same way, using cell lysates of 5 other healthy persons
and other charges of [a-32P]ATP, the basal turnover
rates were 0.635 (CV: 24.6%) and 0.713 (CV: 16.7%);
the corresponding elevation factors were 2.9 (CV:
27.5%) and 3.2 (CV: 12.5%), respectively.
Day to day Variation: The 2'-5'-oligoadenylate syn-
thetase activity in cell lysates from two healthy donors
was determined three and four times during a one-
week period. The turnover rates obtained for the first
person were 0.49,0.59, and 0.41 (mean: 0.496 + 0.07),
CV: 14.8%, and for the second person 0.865, 0.915,
0.76, and 0.78 (mean: 0.83 ± 0.06), CV: 7.6%).
Finally, peripheral blood mononuclear cells from one
person were collected six times during a time period
of two months. The coefficient of Variation of the 2'-
S'-oligoadenylate synthetase levels in these cell lysates
was 24.2%. In this case, the 2/-5/-oligoadenylate syn-
thetase activity of all six samples was estimated on
the same day.
Comparison of the 2'-5'-oligoadenylate syn-
thetase assay according to Schattner with
other assays
Comparison between the Schattner assay (16) and the
assays of Lodemann (14) and Ball (17)
The common feature of these three assays is that 2'-
5'-oligoadenylates formed during the 2'-5'-oligoaden-
ylate synthetase reaction are converted into the cor-
responding 2/-5/-oligoadenylate cores by treatment
with bacterial alkaline phosphatase (fig. 2); this allows
an easier Separation of the reaction products. Table 3
shows that the 2'-5'-oligoadenyläte synthetase levels
obtained with the Schattner assay are lower than those
of the two other assays. This reflects the Situation
that in the Schattner assay part of the radioactivity
incorporated from [32P]ATP into 2'-5'-oligoadenylates
is eliminated during treatment with bacterial alkaline
phosphatase ([32P] on the 5'-end of 2'-5'-oligoadeny-
lates). In contrast, there is no loss of radioactivity in
the Lodemann & Ball assay because [3H]adenosine-
labeled ATP is used äs the Substrate of the 2'-5'-
oligoadenylate synthetase reaction.
Tab. 3. Comparison of the radioactivity incorporated into 2'-
5'-oligoadenylate cores using the assays according to
Schattner, Lodemann and Ball
Cell lysate Schattner Lodemann Ball
assay assay
without interferon-a
15 2.3 + 0.15
30 5.1 ± 0.33
2.8 ± 0.92 background




6.1 ± 0.76 9.8 ± 0.6 9.4 ± 0.8
14.1 ± 1.27 18.1 ± 0.5 23.0 ± 3.3
Lysates were from 2 1Ö7 peripheral blood mononuclear cells,
pretreated or not with 1000 U/ml interferon-a.
Radioactivity incorporated is expressed in % of the radioacti-
vity originally present in ATP.
Comparative estimation of 2'-5'-oligoadenylate synthe*
läse with the assay of Schattner & Knight (radiobinding
assay (15))
In the radiobinding assay, 2'-5'-oligoadenylates (tri-
meric and higher multimeric forms) compete with
2—5A [32P]pCp for binding sites of RNäseL. Figure
5 a shows the calibration curve of this reaction using
Z-S'-oligoadenylate tetramer äs Substrate in the ränge
from 0.5 — 5 nmol 2'-5'-oligoadenylate. For compari-
son of the two assays, the radiobinding assay and the
Schattner assay were carried out in parallel, using
different samples with different amounts of cell lys-
ates; the reaction products formed were sübsequently
estimated according to the methods of the respective
test Systems. Although there is a linear cofrelation of
the turnover rates in both test Systems (coefficient of
correlation r = 0.991) (fig. 5b), the 2'-5'-oligoadeiiy-
late synthetase activities obtained cannot be com^
paired directly, because different reaction products
are measured in the respective assays (Schattner assay:
2'-5'-oligoadenylate cores; radiobinding assay: all
classes of 2'-5'-oligoadenylates, except dimeric fonns).
Example of clinical application: 2'-5'-oli-
goadenylate synthetase levels in peripheral
mononuclear blood cells from children with
chronic myelogenous leukaemia and the in-
fluence of in vitro treatment with interferon
Peripheral blood mononuclear cells from children
with chronic myelogenous leukaemia befofe chemo-
therapy showed very low basal levels (0.1 —0,25, fig.
6). However, after in vitro treatment with interferon,
the 2'«5/-oligoadenyläte synthetase levels were
strongly elevated (up to 35-fold compared to only
2-4 fold in healthy persons, estimated in this set of
experiments).
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0.5 1 25 5
2'-5'-Oligoadenytate Inmot]
Fig. 5 a. Radiobinding assay: calibration curve
x-axis: nmol 2'-5'-oligoadenylate (tetramer), (calibra-
tion Standard)
















































Controls Child 1 Child 2 Child 3
Fig. 6. 2'-5'-Oligoadenylate synthetase catalytic concentrations
in peripheral blood mononuclear cells from three dif-
ferent children with chronic myelogenous leukaemia
before Start of chemotherapy in comparison with heal-
thy controls (1.0).
^ cells pretrated with interferon overnight
01 cells incubated in cell eulture medium overnight







Turnover rate (radiobinding assay),
fraction of total
Fig. 5 b. Correlation between the Sehattner assay and the radio
binding assay. Nine samples containing different
ämounts of 2%5'-oHgoa4enylate synthetase were in-
vestigated in parallel. (Calculation was carried out
under the äpproximate assumption that in the mean
only 2'-5'-oHgoadenyläte trimefs are formed during
the ^-S'-oligoadenylate synthetase feactioh).
Therefore, the 2'-5'-oligoadenylate synthetase levels
fmally obtained after in vitro treatment \vith Inter-
feron were the same magnitüde äs those from healthy
donors.
Discussiop
Assays for the determiiiation of ^-S'-oligoadenylate
synthetase can be classified äs:
1) biological assays (RNA-cleavage assay (21—23),
protein synthesis Inhibition assay (24))
2) binding assays (radiobinding assay (l 5), radioim-
munoassay (25), enzymeimmunoassay (26, 27))
and
3) assays that determine 2/-5'-oligoadenylates formed
during the 2/-5'-oligoadenylate synthetase reaction
(14, 16, 17, 28, 29).
We compared four analytical procedures. From the
binding assays, we chose the radiobinding assay ac-
cording to Knight because all the necessary Substrates
are commercially available. From the third group,
three well established assays were carried out (ac-
cording to Sehattner, Lodemann and Ball).
The direct determination of ^-S'-oligoadenylate syn-
thetase in cell lysates (solution assay, (19)) is restricted
by several factors, mainly enzymic reactions that
either could consume the Substrate of the 2'-5'-oli-
goadenylate synthetase reaction (ATP) or destroy the
products formed (2'-5'-oligoadenylates). Additionally,
because of the small turnover rate of the 2'-5'-oli-
goadenylate synthetase reaction, long incubation
times (several hours) are necessary for a clear signal-
to-noise background. During this prolonged incuba-
tion time, the enzyme is inactivated in solution, but
not if it is fixed to a solid matrix. Therefore, 2'-5'-
oligoadenylate synthetase is usually isolated from cell
lysates using Poly(rI):(rC)-agarose beads. This allows
its rapid isolation from cell lysates without co-isola-
tion of ATP- or 2'-5'-oligoadenylate degrading en-
zymes in ämounts that could influence the test pro-
cedure (tab. 1).
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Summarizing the advantages and disadvantages of all
these procedures, the assay according to Schattner
(16) proved — in our view — to be most suitable for
routine analysis, mainly with regard to its practicality.
Forty to fifty samples in duplicate can be analysed
simultaneously, the preparation of alumina colums
for Separation of 2'-5'-oligoadenylate cores from [32P]
can be performed quickly and easily, and the Sepa-
ration is very effective; blank values are rather low,
allowing the determination of 2'-5'-oligoadenylate
synthetase even for a small turnover of ATP.
This latter point is of special importance, because it
is hardly possible to perform the assay under enzyme-
saturated conditions: Even ATP concentrations äs
high äs 10 mmol/1 (in most assays described ATP
concentrations between l and 3 mmol/1 are used) do
not produce a constant turnover rate in the Michaelis-
Menten plot (data not shown). Therefore, measure-
ment at a low ATP turnover, provides less opportunity
for variations in the velocity of the enzyme reaction.
Based on these theoretical considerations and on our
own practical experiences with this test System, in^
cubation conditions that lead to an ATP turnover
between 5 and 15% can be recommended for optimal
test performance. This can be achieved, e. g. by using
extracts from about 4 l O5 peripheral blood mono-
nuclear cells and 5—20 hours incubation time.
The following points concerning the reproducibility
of the Schattner assay are worth noting. Using a
freshly prepared Charge of [32P]ATP, the day to day
Variation of the 2/-5/-oligoadenylate synthetase levels
are relatively small within the first days, but with
increasing Prolongation of storage time, the turnover
rates decrease; this is probably due to the increasing
decomposition of ATP by radiolysis. Because all turn-
over rates are related to the same internal Standard,
this fact is not a severe problem.
In the experiments described above, an internal Stand-
ard was always established for each new set of experi-
ments (i. e. for each new Charge of [32P]ATP). How-
ever, because 2'-5'-oligoadenylate synthetase-contain-
ing cell lysates can be stored at —70 °C for a long
period of time, it should be possible to use the same
internal Standard for several sets of experiments. This
is especially recommended if the 2'-5'-oligoadenylate
synthetase is monitored during long term interferon
therapies.
In contrast to its practicability, the Schattner assay
hasche following severe theoretical limitatiön. It is
not possible to estimate the 2'-5'-oligoadenylate syn-
thetase activity exactly, because more than one class
of 2'-5'-oligoadenylates are formed during the 2'-5'-
oligoadenylate synthetase reaction; after treatment
with bacterial alkaline phosphatase, only 50% of the
radioactivity originally incorporated into the dimeric
form can be registrated (ppp*Ap*A — > Ap*A + P*
+ 2P), only two thirds of the triineric form
(ppp*Ap*Ap*A -> Ap*Ap*A + P* + 2P) and so
on. Although the 2'-5'-oligoadenyi£te synthetase ac-
tivity using the Schattner assay is often expressed äs
ATP turnover rate, this is not valid, because the
composition of the 2'-5'-oligoadenylates generated
during any 2'-5'-oligoadenylate synthetase reaction is
unknown. The correct way to express the turnover
rate of the 2'-5'-oligoadenylate synthetase reaction is
therefore to estimate the percent radioactivity incor-
porated from ATP into 2'-5'-oligoadenylate cores. Be-
cause all samples are related to internal Standards and
are measured in the same way, this evalüation is
sufficiently correct.
The problem described does not exist in the two öther
assays, which are carried out according to the same
test principle, but using [3H]-(adenosine)-labeled ATP.
In the Lodemann assay (14), the 2'-5'-oligoadeüylates
are separated from [3H]adenosine by DEAE-ion ex-
change chromatography. The only drawbäck of this
assay is that it is not äs easy to handle äs the Schattner
assay (column preparation and elution procedüre);
this is especially inconvenient when a large number
of samples has to be processed. Nevertheless, this test
allows the exact determination of the ATP turnover
rate and the use of [3H]ATP instead of [32P]ATP has
certain advantages.
The third assay in this group, the assay of Ball &
White (17), is most easily performed, because after
treatment with bacterial alkaline phosphatase the 2'-
S'-oligoadenylate cores are only spotted on DEAE-
ion-exchange filters; the [3H]adenösine residues are
removed from the filters by a simple washing proce-
düre using H2O. Unfortunately, the sensitivity of this
test is limited (high background values). Therefpre,
small turnover rates cannot be detected and its re^
producibility was-in our hand-worse than that of the
two other assays described above.
The fourth assay investigated, the radiobinding assay
according to Knight (15) is very sensitive, but there
are some disadvantages. A calibration curve must
always be established, and it is recommended that the
test be performed using several sample dilutions in
order to get 2/-5/-oligoadenylate concentrations well
fitted in the calibration curve ränge. The test is based
on the binding of oligoadenylates to RNaseL present
in high amounts in reticulocyte lysates. However, di-
meric 2'-5'-adenylates do not bind, and therefore, they
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cannot be detected. Thus, the test gives Information
only about the amount of biologically active oligoad-
enylates, and an exact determination of the turnover
rate of the 2'-5'-oligoadenylate synthetase reaction is
not possible.
Furthermore, we investigated the possibility of üsing
an ATP chemiluminescence assay for the determina-
tion of 2/-5'-oligoadenylate synthetase (30), in order
to avoid handling radioactivity (data not shown).
Although the determination of ATP (its decrease dur-
ing the 2'-5'-oligoadenylate synthetase reaction) is
more advantageous than the determination of the
heterogeneous 2'-5'-oligoadenylates, a relatively high
ATP turnover is necessary in order to get Signals
clearly distinguishable from the ATP signal at the
Start of the reaction. However, äs already mentioned,
it is hardly possible to perform the 2'-5'-oligoadeny-
late synthetase reaction under Saturation conditions
and therefore, the general applicability of the ATP
chemiluminescence assay is restricted.
For clinical investigations, two types of Information
can be obtained by the 2'-5'-oligoadenylate synthetase
assay:
1) The basal levels of 2'-5'-oligoadenylate synthetase
in peripheral mononuclear blood cells from pa-
tients, expressed relative to Standards (healthy per-
son, set äs 1.0).
2) The elevation factor, expressed äs the ratio of 2'-
5'-oligoadenylate synthetase levels before and after
in vitro treatment of cells with interferon. The
determination of this factor provided very useful
additional information, e. g. compared with valües
obtained from healthy persons, this factor was
found to be reduced in peripheral mononuclear
blood cells from patients with acquiired immuno-
deficiency syndrome (AIDS) (8) or from children
with severe immunodeficiency syndrome (20). The
elevation factor is influenced by several parameters
(type of interferon; type of foetal calf serum used
for incubation; incubation time); additionally, it
made a considerable difference to the results if the
cell lysate of the peripheral blood mononuclear
cells, which was not treated with interferon, was
prepared immediately after Isolation from periph-
eral blood or after a simultaneous overnight in-
cubation using an interferon-free medium. In all
experiments described here, untreated peripheral
blood mononuclear cells were used after overnight
incubation.
In our own investigations described above, the basal
levels of 2'-5/-oligoadenylate synthetase in peripheral
blood mononuclear cells from children with chronic
myelogenous leukaemia were found to be strongly
reduced, compared with healthy controls. This is in
agreement with the Suggestion that 2'-5'-oligoadeny-
late snythetase (äs part of the antiproliferative 2'-5'-
oligoadenylate System) is low in undifferentiated and
proliferating cells. However, these low basal levels can
be elevated drastically after in vitro treatment with
interferon. Independently of its diagnostic signifi-
cance, the biological importance of this elevation re-
mains to be clarified, because the elevation of 2'-5'-
oligoadenylate synthetase alone is not in itself suffi-
cient to produce antiproliferative (or antiviral) effects;
oligoadenylates can be formed and the 2'-5'-oligoad-
enylate System becomes operative, only in the presence
of dsRNA. It can be speculated that mRNAs coding
for proteins engaged in proliferative processes (e. g.
from oncogenes or growth factors) could serve äs
target molecules for the selective attachment and ac-
tivation of the 2'-5'-oligoadenylate synthetase, pro-
vided that these mRNAs can form partial double
stfanded chains (e.g. by chain refolding). Such a
mechanism is possibly responsible for the selective
degradation of the myc-oncogene mRNA, observed
after interferon treatmefit of lymphoblastoid Daudi
cells (31^34). Whether this principle may also play
a role in chronic myelogenous leukaemia, or other
malignant diseases influenced by interferon, is still an
open question.
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